ResearcherShanghai First People's HospitalNo recent work listed

Zhanshan Wang

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2020: 1 paper

Papers 1

Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. Co-author DOI 10.3892/ol.2020.11300 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guangtao Luo · 1 shared paper, 2020 · strength 0.19
- Paper Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. DOI 10.3892/ol.2020.11300 ↗
Zhengjun Qiu · 1 shared paper, 2020 · strength 0.19
- Paper Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. DOI 10.3892/ol.2020.11300 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.